Basecamp Research secures $140m for AI-driven therapies

Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development. The latest funding would also support an expansion of Basecamp’s pharmaceutical partnerships. Basecamp’s initial therapeutic focus is in vivo cell therapy, which involves reprogramming the cells of a patient inside the body. Credit: Basecamp Research. UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development. S32 led the oversubscribed financing round.…

Source: Pharmaceutical Technology